Stephan Christgau is founding partner of Eir Ventures, a new Nordic life science focused venture fund launched in 2020. Prior to joining Eir Ventures, Stephan worked twelve years in Novo Holdings, a Danish asset management company owned by the Novo Nordisk Foundation, where he co-founded Novo Seeds, the early stage investment and company creation team of Novo Holdings. Stephan obtained his MSc degree from the Technical University of Denmark in 1988 and his PhD degree in 1992 from the Technical University of Denmark, for a project in diabetes immunology, conducted at Hagedorn Research Institute and University of California, San Francisco. Prior to joining Novo Seeds, Stephan was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. He also played an active role in the company’s financing including a public listing in the USA on the OTC exchange through a reverse merger with a public shell company. Previously Stephan has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S.
Stephan has led investment and transactions in numerous companies and served on the Boards of companies such as Epitherapeutics ApS (sold to Giliead), Orphazyme A/S, Afyx A/S, Aros Pharma ApS, Pcovery ApS, Forendo Pharma OY, Galecto Biotech AB, IO Biotech ApS, Acesion ApS, Macrophage Pharme Ltd, Heparegenix GmbH and Lysogene SA. He also serves as chairman for VentureCup, a Danish non-profit university entrepreneurship organization.